Robert J. Hoyer

577 total citations
10 papers, 319 citations indexed

About

Robert J. Hoyer is a scholar working on Oncology, Molecular Biology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Robert J. Hoyer has authored 10 papers receiving a total of 319 indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Oncology, 4 papers in Molecular Biology and 3 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Robert J. Hoyer's work include Cancer Immunotherapy and Biomarkers (3 papers), Lung Cancer Research Studies (3 papers) and Advanced Breast Cancer Therapies (2 papers). Robert J. Hoyer is often cited by papers focused on Cancer Immunotherapy and Biomarkers (3 papers), Lung Cancer Research Studies (3 papers) and Advanced Breast Cancer Therapies (2 papers). Robert J. Hoyer collaborates with scholars based in United States, Australia and Hungary. Robert J. Hoyer's co-authors include Kwong Y. Tsang, John L. Marshall, Mary Ann Toomey, Ellen Richmond, Jeffrey Schlom, Edmund A. Gehan, Ronald A. Peck, Philip M. Arlen, Ping Chang and Nelson Leung and has published in prestigious journals such as Journal of Clinical Oncology, British Journal of Cancer and Annals of Oncology.

In The Last Decade

Robert J. Hoyer

10 papers receiving 309 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Robert J. Hoyer United States 5 241 172 122 80 40 10 319
MingZhu Zhu United States 4 244 1.0× 135 0.8× 104 0.9× 65 0.8× 30 0.8× 6 295
Joanne P. McLaughlin United States 6 358 1.5× 156 0.9× 165 1.4× 128 1.6× 67 1.7× 6 405
Timothy T. Spear United States 10 240 1.0× 194 1.1× 107 0.9× 60 0.8× 66 1.6× 18 354
Flora Wang United States 5 402 1.7× 222 1.3× 238 2.0× 24 0.3× 27 0.7× 6 480
Gabriel R. Starbeck-Miller United States 9 374 1.6× 154 0.9× 67 0.5× 23 0.3× 26 0.7× 9 431
Ling-Yu Kuan United States 4 251 1.0× 192 1.1× 70 0.6× 21 0.3× 30 0.8× 5 333
Michael T. Lotze United States 8 301 1.2× 158 0.9× 114 0.9× 42 0.5× 19 0.5× 10 405
Maik Haentschel Germany 6 146 0.6× 72 0.4× 172 1.4× 56 0.7× 19 0.5× 9 367
Céline Halluard France 4 145 0.6× 133 0.8× 118 1.0× 79 1.0× 15 0.4× 7 303
Jana Bieblová Czechia 12 363 1.5× 190 1.1× 187 1.5× 31 0.4× 10 0.3× 33 499

Countries citing papers authored by Robert J. Hoyer

Since Specialization
Citations

This map shows the geographic impact of Robert J. Hoyer's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Robert J. Hoyer with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Robert J. Hoyer more than expected).

Fields of papers citing papers by Robert J. Hoyer

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Robert J. Hoyer. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Robert J. Hoyer. The network helps show where Robert J. Hoyer may publish in the future.

Co-authorship network of co-authors of Robert J. Hoyer

This figure shows the co-authorship network connecting the top 25 collaborators of Robert J. Hoyer. A scholar is included among the top collaborators of Robert J. Hoyer based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Robert J. Hoyer. Robert J. Hoyer is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

10 of 10 papers shown
1.
Day, Daphne, Vinod Ganju, Ki Y. Chung, et al.. (2025). First-in-human phase I study of EMB-02, a bispecific antibody targeting PD-1 and LAG-3 in patients with advanced solid tumors. British Journal of Cancer. 132(10). 905–912. 3 indexed citations
2.
Leal, Alexis D., Patrick J. Blatchford, Robert W. Lentz, et al.. (2025). Phase II study of cabozantinib and nivolumab in refractory metastatic microsatellite stable (MSS) colorectal cancer (CRC).. Journal of Clinical Oncology. 43(4_suppl). 229–229. 1 indexed citations
3.
Day, Daphne, Vinod Ganju, Ki Y. Chung, et al.. (2023). 1028P Preliminary phase I results from a first-in-human study of EMB-02, a PD-1xLAG-3 bispecific antibody, in patients (pts) with advanced solid tumors. Annals of Oncology. 34. S625–S625. 4 indexed citations
4.
Boyer, Michael, Sandip H. Patel, Thomas U. Marron, et al.. (2021). 456 A phase 1b/2 umbrella study of anti-PD-1 sasanlimab in combination with other therapies for patients with stage IIIB/IV non-small cell lung cancer (NSCLC): The LANDSCAPE 1011 trial in progress. Regular and Young Investigator Award Abstracts. A484–A484. 1 indexed citations
5.
Dragnev, Konstantin H., Taofeek K. Owonikoko, Tibor Csőszi, et al.. (2018). Trilaciclib (T) decreases multi-lineage myelosuppression in extensive-stage small cell lung cancer (ES-SCLC) patients receiving first-line chemotherapy. Annals of Oncology. 29. viii597–viii597. 1 indexed citations
6.
Hart, Lowell L., Patrick J. Roberts, Renata Ferrarotto, et al.. (2017). P1.07-002 G1T28, a Cyclin Dependent Kinase 4/6 Inhibitor, in Combination with Topotecan for Previously Treated Small Cell Lung Cancer: Preliminary Results. Journal of Thoracic Oncology. 12(1). S696–S696. 1 indexed citations
7.
Lima, Caio Max S. Rocha, Patrick J. Roberts, Victor Priego, et al.. (2017). Trilaciclib (G1T28): A cyclin dependent kinase 4/6 inhibitor, in combination with etoposide and carboplatin (EP) for extensive stage small cell lung cancer (ES-SCLC)—Phase 1b results.. Journal of Clinical Oncology. 35(15_suppl). 8568–8568. 8 indexed citations
8.
Hoyer, Robert J., Nelson Leung, Thomas E. Witzig, & Martha Q. Lacy. (2007). Treatment of diuretic refractory pleural effusions with bevacizumab in four patients with primary systemic amyloidosis. American Journal of Hematology. 82(5). 409–413. 14 indexed citations
9.
Hoyer, Robert J., Amindra S. Arora, & Todd H. Baron. (2005). Complications after traction removal of direct percutaneous endoscopic jejunostomy: three case reports. Gastrointestinal Endoscopy. 62(5). 802–805. 6 indexed citations
10.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by MingZhu Zhu Breakdown of academic impact, for papers by Joanne P. McLaughlin Breakdown of academic impact, for papers by Timothy T. Spear Breakdown of academic impact, for papers by Flora Wang Breakdown of academic impact, for papers by Gabriel R. Starbeck-Miller Breakdown of academic impact, for papers by Ling-Yu Kuan Breakdown of academic impact, for papers by Michael T. Lotze Breakdown of academic impact, for papers by Maik Haentschel Breakdown of academic impact, for papers by Céline Halluard Breakdown of academic impact, for papers by Jana Bieblová
Rankless by CCL
2026